Effects of the subcutaneous administration of enkephalins on tail-flick response and righting reflex of developing rats.
The s.c. administration of [Met5]-enkephalin to 10-day-old rats pretreated with the mixture of 3 peptidase inhibitors, amastatin, captopril and phosphoramidon, produced the inhibition of tail-flick response and loss of righting reflex. When infant rats were pretreated with the mixture of any combination of two peptidase inhibitors, however, the change in both the response and the reflex were not produced at all by enkephalin injection, indicating that 3 kinds of enzymes, amastatin-sensitive aminopeptidase(s), captopril-sensitive peptidyl dipeptidase A and phosphoramidon-sensitive endopeptidase 24.11, played an important role in the inactivation of enkephalin after its systemic administration. Additionally, the fact that the two enkephalin-induced effects were more effectively antagonized by naloxone, a relatively selective mu-opioid antagonist, than by naltrindole, a specific delta-antagonist, or by nor-binaltorphimine, a specific kappa-antagonist, showed that these two effects were produced by the interaction of enkephalin with mu receptors. Moreover the involvement of mu receptors in the production of these two effects was shown by the fact that the s.c. administration of [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin, a selective mu agonist, also produced these two effects which were more effectively antagonized by naloxone than by naltrindole or nor-binaltorphimine. Since the magnitude of the two effects induced by enkephalins in 15-day-old rats was significantly lower than that in 10-day-old rats, and the two enkephalin-induced effects were not produced at all in 20-day-old rats, a maturation-induced decrease in the permeability of the blood-brain barrier against opioid peptides was indicated.
Oka
T
T
Department of Pharmacology, School of Medicine, Tokai University, Isehara, Japan.
Liu
X F
XF
Kajita
T
T
Ohgiya
N
N
Ghoda
K
K
Taniguchi
T
T
Arai
Y
Y
Matsumiya
T
T
D000375:Aging / Q000502:physiology*; D000818:Animals; D000900:Anti-Bacterial Agents; D002216:Captopril / Q000494:pharmacology; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004744:Enkephalin, Methionine / Q000008:administration & dosage / Q000494:pharmacology*; D004745:Enkephalins / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006020:Glycopeptides / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D010146:Pain / Q000503:physiopathology*; D010455:Peptides; D011187:Posture; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012018:Reflex / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D004745:Enkephalins; D006020:Glycopeptides; D009842:Oligopeptides; D010455:Peptides; D011480:Protease Inhibitors; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004744:Enkephalin, Methionine; C016977:amastatin; D002216:Captopril; C008890:phosphoramidon